close

Agreements

Date: 2012-04-23

Type of information: Licensing agreement

Compound: Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics

Company: Alnylam Pharmaceuticals (USA - MA) Plant Bioscience Limited (UK)

Therapeutic area:

Type agreement:

licensing

Action mechanism:

Disease:

Details:

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, and Plant Bioscience Limited (PBL), a technology development and intellectual property management company, have entered into a licensing agreement. PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics. U.S. Patent No. 8,097,710 issued in January 2012, and is the most recently issued patent in PBL’s IP estate in short RNAs derived from the seminal work of Prof David Baulcombe and Dr Andrew Hamilton, at The Sainsbury Laboratory (Norwich, UK).

Financial terms:

Financial terms were not disclosed.

Latest news:

Is general: Yes